*Data updated daily at 18:00 EAT
Yemaachi Biotech, a cancer research and diagnostics company has raised USD 3 Mn in an initial round of funding to help it achieve its aim of global accuracy oncology diversification. V8 Capital led the round, which included LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital, and Ethan Perlstein as investors.
Yemaachi was founded with the purpose of improving precision oncology across Africa and beyond by boosting access to research and diagnostics. The company also provides clinical testing services tailored to indigenous people’s needs, such as NGS-based screening and diagnostic testing.